ROCKVILLE, Md. and Hong Kong (April 2, 2019) – RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), a Hong Kong based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee’s Pharm previously licensed RGN-259, RegeneRx’s sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES), neurotrophic keratitis (NK), and other persistent corneal disorders, in China, Taiwan, Macau, and Hong Kong.
English 
Thai